First participants randomized in AskBio Phase II gene therapy trial for Parkinson’s diseaseBerlin, Germany, and Research Triangle Park, N.C., USA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Not intended for UK Media
AskBio to collaborate with Belief BioMed to explore the potential of new gene therapiesBerlin, Germany, and Research Triangle Park, N.C., USA, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media
AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting 2024Four oral and five poster presentations demonstrate breadth and progress of AskBio’s gene therapy research, development, and clinical activities
AskBio Names Mansuo Shannon Chief Scientific OfficerResearch Triangle Park, N.C., April 09, 2024 (GLOBE NEWSWIRE) --
First patient randomized in AskBio Phase II gene therapy trial for congestive heart failureBerlin, Germany and Research Triangle Park, NC, USA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media
AskBio Announces Initiation of Phase 2 GenePHIT Trial in Congestive Heart Failure (CHF)GenePHIT, which is now enrolling, will study AB-1002 in adults with NYHA Class III Heart Failure and non-ischemic cardiomyopathy
AskBio Phase Ib trial of AB-1005 gene therapy in patients with Parkinson’s disease meets primary endpointBerlin, Germany/Research Triangle Park, North Carolina, USA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media
